Developing Differentiated Medicines 

PureTech is developing medicines for devastating diseases including intractable cancers, lymphatic, GI diseases, CNS disorders, inflammatory and immunological diseases.

Exploring the Brain Immune Gut (BIG) axis

23 product candidates

14 are clinical stage

1 FDA cleared product

Relationships with major pharma companies

Amgen Lilly Merck Boehringer Ingelheim Bristol-Myers Squibb Janssen Roche

Team of industry leaders and experts

Publications
Publications
Nature Neuroscience: CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature
Publications
Internal Pipeline
PureTech's Lymphatic Leap
Publications
Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation
Press releases
2020-01-23
PureTech Receives $200 Million from Sale of a Minority Portion of Affiliate Shares

Continue

Press releases
2020-01-15
PureTech Affiliate Akili Announces New AKL-T01 Study Achieved Primary Endpoint in Children with ADHD

Continue

Press releases
2019-12-19
PureTech Health Affiliate Follica Announces Positive Topline Data from Clinical Study in Male Androgenetic Alopecia

Continue